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Abstract
The ability to deliver cells to appropriate target tissues is a prerequisite for successful cell-based therapy. To optimize cell
therapy it is therefore necessary to develop a robust method of in vivo cell delivery quantification. Here we examine
Mesenchymal Stem Cells (MSCs) labeled with a series of 4 membrane dyes from which we select the optimal dye
combination for pair-wise comparisons of delivery to inflamed tissue in the mouse ear using confocal fluorescence imaging.
The use of an optimized dye pair for simultaneous tracking of two cell populations in the same animal enables
quantification of a test population that is referenced to an internal control population, thereby eliminating intra-subject
variations and variations in injected cell numbers. Consistent results were obtained even when the administered cell
number varied by more than an order of magnitude, demonstrating an ability to neutralize one of the largest sources of
in vivo experimental error and to greatly reduce the number of cells required to evaluate cell delivery. With this method, we
are able to show a small but significant increase in the delivery of cytokine pre-treated MSCs (TNF-a & IFN-c) compared to
control MSCs. Our results suggest future directions for screening cell strategies using our in vivo cell delivery assay, which
may be useful to develop methods to maximize cell therapeutic potential.
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Introduction
Cell-based therapeutics offer the potential to address unmet
clinical needs in which traditional health care has faltered. Cellular
therapies have been explored in pre-clinical and clinical models,
and demonstrated promise in diseases such as lung injury [1],
myocardial infarction [2,3], graft versus host disease [4,5], and
sepsis [6]. However, very few clinical applications have been
approved so far, which suggests that treatment efficacy could be
improved. One of the primary strategies to improve therapeutic
outcome is by increasing delivery of cells to their target tissue. To
do so, methods such as alternative culture [7,8], pretreatment with
cytokines [9,10,11], transfection [12,13,14], or cell engineering
[15,16,17,18] have been used. Our lab has primarily focused on
cell surface engineering of therapeutic mesenchymal stem cells
(MSCs), and has found that functionalization of the MSC surface
can enhance their delivery to an inflamed site in vivo [18].
To evaluate the delivery of potential cell therapeutics in vivo,
the most common techniques are radiolabeling [19,20], biolumi-
nescence [21,22,23,24], fluorescent protein expression
[25,26,27,28,29], and exogenous fluorescence labels
[17,18,30,31]. Of these, only fluorescent protein expression and
exogenous fluorescence labeling have been demonstrated to have
adequate sensitivity for single cell detection in vivo. Fluorescent
protein expression is a powerful technique when purification of
cells from transgenic mice or transfection using lentivirus is
possible. However, transfection can yield variable fluorescent
protein expression [32,33] and impact cell function [34], and as
such is not optimal for all applications. Therefore, to track cell
delivery to inflamed tissues, we stain the cell membrane with
lipophilic membrane dyes and image the cells in vivo using
confocal microscopy. Single cell detection using confocal micros-
copy allows dynamic and quantitative tracking of cells in vivo, an
important capability in the evaluation of cell modification
strategies and elucidation of biological mechanisms. Previously
published research by our group and others has demonstrated the
usefulness of this strategy to evaluate the impact of cell surface
engineering in vivo using MSCs. In particular, studies by
Sackstein et al. and Sarkar et al. found that surface engineering
of MSCs stained with lipophilic membrane dyes enhanced delivery
to the bone marrow via enzymatic modification and to the
inflamed ear via Sialyl Lewis
x chemical modification, respectively
[18,30].
One significant advantage of fluorescent cell labels is the ability
to detect multiple colors at once, a strategy leveraged by Sarkar
et al. When combined in an optimized dye pair, simultaneously
administered modified and control cells can be quantified, which
allows each animal to serve as its own control and limits animal-to-
animal variability. The aim of this study is to select the optimal dye
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e78145pair combination from a series of 4 membrane stains for
quantifying cell delivery to inflamed tissue using MSCs by
elucidating the practical optical characteristics of each cell tracking
dye from visible to near-IR emission. Our results will improve the
ability of researchers to quantify and optimize in vivo cell homing
behavior.
Results and Discussion
In Vitro MSC Staining and Viability
To determine the relative staining efficiency in vitro, stained
MSCs were mixed in equal quantities at 10
6 cells/mL for each
color, imaged on a glass slide, and displayed simultaneously
(Fig. 1a). In each frame, all MSCs were stained as determined by
comparison with the reflectance channel. Quantification of cell
numbers (n<100 for each color, from a total of ,20 fields of view)
shows that about equal number of cells are detected in each color
(Fig. 1b). Direct insertion of the dyes into the cell membrane had a
limited impact on viability versus the unstained control (p,0.05,
Tukey’s HSD) as measured by metabolic activity using MTS with
minimal difference between stains (,80% of unstained for all,
Fig. 1c).
MSC Trafficking to Inflamed Ears
To evaluate the performance of lipophilic dyes for use in
quantifying cell delivery to an inflamed site, 7610
4 MSCs stained
with each of the range of dyes were systemically infused. By
imaging in the inflamed ear, cells labeled with all four stains can be
visualized, as displayed using a maximum intensity projection of
the 3D stacks (Fig. 2a). Cell counting was performed on individual
channels in the 3D stack with contrast enhanced to enable
detection of all events, after first excluding autofluorescent cells
which typically showed up as low-intensity objects distributed
across than one channels. Upon quantification (Fig. 2b), a
difference between the detected number of cells for the stains
was observed (p,0.05, 1-way ANOVA). The largest number of
MSCs were detected with DiI staining (168616 cells/mm
2),
followed by DiD (144611 cells/mm
2), DiO (128611 cells/mm
2)
and DiR (103614 cells/mm
2). Higher tissue autofluorescence
background at shorter wavelengths likely contributed to the lower
sensitivity for DiO. Interestingly, the advantages of diminished
autofluorescence and better tissue penetration with increasing
wavelength did not lead to higher cell counts for DiR, most likely
due to the reduced quantum efficiency of our PMTs at
wavelengths .700 nm. These results suggest that in terms of
detected counts in the inflamed ear, the optimal dye pair for future
use is DiI and DiD.
Depth Dependence of Detection
To better characterize how the detection sensitivity varies with
wavelength, we next evaluated the depth dependence of detection
for the range of MSC stains. This depth distribution of detected
cells is a function of the staining intensity, the detection sensitivity
of the system at the wavelength of interest, and the scattering
properties of the tissue at the excitation/emission wavelengths.
Interestingly, little difference can be observed between the cell
colors in the depth histogram shape and mean depth (Fig. 3a).
Since our LPS injection is in the subcutaneous space on one side of
the ear (mouse ears are ,200 mm in thickness with collagen
support in the center), it is likely that the average depth of detected
MSCs of 58 mm is the actual location of the cells. This suggests
that the majority of the cells are located at depths sufficiently
shallow to be detected regardless of the stain. However, if only the
deepest cells are investigated (.100 mm deep), an increase in the
proportion of detected cells is observable with increasing dye
emission wavelength (Fig. 3a), which is expected due to the
decreased scattering and absorption at longer wavelengths.
Additionally, if MSC intensity is examined as a function of depth
and normalized to the brightest cells, an increase in intensity for
the longest wavelength DiR stained cells is found at the deepest
locations (Fig. 3b). This result is supported by a simple model
prediction based on scattering and absorption coefficients reported
in the literature for mouse ears with our excitation and peak
emission wavelengths [35]. To do so, we used the formula.
I~e{z(m’s{inzma{inzm’s{outzma{out)
where the relative signal intensity (I) is a function of depth (z, mm),
reduced scattering coefficient for excitation (m’s{in,m m
21) and
emission (m’s{out,m m
21), and absorption coefficient for excitation
(ma{in,m m
21) and emission (ma{out,m m
21). At a depth of
135 mm, this approximation would suggest a remaining intensity of
29% for DiO, 31% for DiI, 38% for DiD, and 44% for DiR. Our
experimental results at 135 mm align well with predicted values
(3169% for DiO, 3969% for DiI, 42620% for DiD, and
54620% for DiR), but with increased error due to the small
number of cells that are found at 135 mm depth. These results
suggest future work to more carefully investigate contributing
factors to accurately model our imaging scheme and determine
relative contributions of all optical and electronic parameters [36].
Since DiI and DiD exhibited the highest intensity and counts, this
dye pair was selected for subsequent experimentation.
Figure 1. MSC staining in vitro. In vitro imaging characteristics of MSCs stained with lipophilic membrane dyes (a). Mixing equal quantities of the
cells yielded similar levels of detected cells (b). Despite a small decrease in viability from the unstained control (p,0.05, Tukey’s HSD), there was
minimal difference between viability of cells after staining as measured by MTS (c). Scale bar=100 mm.
doi:10.1371/journal.pone.0078145.g001
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treatment
One strategy to increase the delivery of MSCs to diseased sites is
to pre-treat the cells with a small molecule or cytokine that will up-
regulate or activate homing mechanisms of the MSC. As a proof of
concept to demonstrate the usefulness of our optimized DiD/DiI
dye pair in evaluating MSC homing to the inflamed ear, a
cytokine cocktail of TNF-a & IFN-c was used. Both molecules are
well accepted to activate MSC function and homing
[37,38,39,40], and were introduced to the cell media in vitro
24 h before infusion (10 ng/mL each). Use of a dye switch with
correction for the dye efficiency as described in the materials and
methods section allowed direct comparison between the numbers
of MSCs detected in the inflamed ear. As shown in Fig. 4a,b, a
statistically significant increase of 2262% was found in the
delivery of TNF-a/IFN-c -treated MSCs to the inflamed site as
compared to the control MSCs (p,0.05, unpaired Students t-test).
The effect remained with a commensurate reduction in detected
cell counts (p,0.05, 2- way ANOVA) when progressively fewer
cells were systemically infused from 5610
5 cells down to 1610
4
cells, which is highlighted by plotting the average ratio of pre-
treated MSCs to control MSCs in the inflamed ear at each dose
(Fig. 4c,d). An increase in cell delivery this small would likely
remain undetected if only a single cell population was analyzed per
mouse (i.e. without the co-infusion of treated and control cells
labeled with the DiI/DiD dye pair) due to variability among
individual animals that could result from parameters such as cell
infusion number and the severity of inflammation. These results
indicate the power of our technique to neutralize one of the largest
sources of in vivo experimentation variability, and build on a
previous report demonstrating a larger enhancement of MSC
trafficking to inflamed sites [18]. Additionally, validating the
injection of significantly fewer cells than the 1610
6 per mouse or
more commonly used to analyze homing behavior, substantially
reduces experimentation burden allows more efficient testing of
cell delivery strategies, and more closely mimics cell loading used
in human clinical trials [10,17,18,19,21,28,41]. To further
increase the throughput potential of our validated inflamed ear
quantification technique, future work will pursue automation of
cell counting by tailoring techniques described in published cell
counting studies [42,43,44] to the high background imaging
environment of the skin.
Conclusions
This work demonstrates an optimized corrected dye pair to
generate robust quantification of cell delivery to target the
inflamed mouse ear using primary human MSCs. We have shown
that a range of lipophilic membrane dyes yield consistent staining
in vitro and in vivo, and have minimal impact on viability in vitro.
We have determined that the bulk of MSCs detected in the dermal
layers of the skin appear to be within 55–60 mm of depth, that
longer wavelength dyes allow detection of higher numbers of cells
deep in the tissue, and the optimal nature of the DiI/DiD dye pair
in our system. To apply our findings, we demonstrated increased
homing that was consistent across cell injection number for MSCs
pretreated with TNF-a/IFN-c, with use of a dye ratio to correct
for injection number and provide a robust quantification of
homing improvement. Our optimized assay was able to detect a
small increase in cell delivery, and could improve experimental
throughput in the future by substantially reducing the number of
cells needed for investigation of cell engineering strategies. This
knowledge can be used to determine the efficacy of further cell
engineering approaches to improve cell trafficking to target tissue,
and may help yield novel therapeutics and cell delivery strategies
in the future.
Materials and Methods
Cell Staining and Viability
To allow tracking of MSCs, cells were stained with a range of
lipophilic membrane dyes with emission wavelengths in the green
(DiO, extinction coefficient=154,000 cm
21M
21 in MeOH), red
(DiI, extinction coefficient=148,000 cm
21M
21 in MeOH), far
red (DiD, extinction coefficient=193,000 cm
21M
21 in MeOH),
and near-IR (DiR, extinction coefficient=270,000 cm
21M
21 in
MeOH) (Invitrogen, Carlsbad, CA). Primary human MSCs were
suspended at a concentration of 10
6 cells/mL and incubated with
Figure 2. MSC delivery to an inflamed site in vivo. Intravenously infused MSCs stained with a range of lipophilic membrane dyes appear in the
inflamed ear 24 h after administration. High numbers of MSCs are present in the inflamed ear for each color (a). A stain-dependent difference in
detected cell numbers was found (p,0.05, 1-way ANOVA), where DiI and DiD yielded the highest counts in the ear with DiO and DiR having relatively
fewer cells detected (b). Scale bar=100 mm.
doi:10.1371/journal.pone.0078145.g002
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PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e78145Figure 3. Stained MSC depth detection dependence. When the depth dependence of detection for MSCs dyed with each stain is analyzed, no
discernable difference in the depth histogram or in the average MSC depth is observable (a). However, a modest increase in the number of MSCs
detectable below the depth of 100 mm appears with longer wavelength dyes. Normalized intensity of cells analyzed over depth indicates a close
match between experimental results and theoretical predictions, with an improvement in the intensity retention of the near-IR emitting DiR labeled
cells (b). Average signal intensity revealed a lower intensity for DiO- likely due to high background near the skin surface and signal degradation at
greater depth- and for DiR. However, DiR intensity was mostly recovered when corrected for detector quantum efficiency, suggesting the importance
of detector characteristics in cell detection.
doi:10.1371/journal.pone.0078145.g003
In Vivo Quantification of MSC Delivery
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e7814510 mM Vybrant DiO, 10 mM Vybrant DiI, 10 mM Vybrant DiD,
or 15 mM Vybrant DiR in 16PBS+0.1% BSA for 20 minutes at
37uC. The MSCs were then washed twice in 16PBS and mixed in
equal numbers for imaging in vitro or in vivo at a concentration of
1610
7 cells/mL To investigate the impact of lipophilic membrane
stains on MSC health, cell viability was tested using the metabolic
activity stain MTS according to standard protocols. Equal
numbers of the stained MSCs were placed in individual wells in
triplicate and incubated 24 h in media at 37uC. The formazan-
based reagent was added for 4 h and viability was assessed by
absorbance at 590 nm.
In Vivo MSC Homing
C57BL/6 mice (Charles River Laboratories, Wilmington, MA)
were anesthetized with ketamine/xylazine and their ears shaved
24 h prior to cell infusion. To induce an inflammatory response,
30 mg of E. coli lipopolysaccharide (LPS, Sigma, St. Louis, MO) in
50 mL saline was injected into the pinna of the left ear, with 50 mL
0.9% saline injected into the right ear as a control. For in vivo dye
sensitivity validation, 70,000 cells of each stain were suspended in
150 mL PBS (pH 7.4) and injected by retro-orbital vein infusion.
Studies were in accordance with US National Institutes of Health
guidelines for care and use of animals under approval of the
Institutional Animal Care and Use Committees of Massachusetts
General Hospital and Harvard Medical School.
To evaluate the impact of cytokine pre-treatment of MSC
homing to the inflamed ear, MSCs were incubated with 10 ng/
mL each of TNF-a and IFN-U for 24 h before staining and in vivo





5) each of cytokine pre-treated
cells and control cells stained with DiI or DiD with a dye switch.
To highlight the vasculature, 50 mL of 10 mg/mL FITC-dextran
(2610
6 kDa; Sigma, St. Louis, MO) was injected retro-orbitally
prior to imaging.
Confocal Fluorescence Microscopy
In vitro staining and in vivo homing of stained MSCs to the skin
was imaged noninvasively in real time using a custom-built video-
rate laser-scanning confocal microscope [45]. For this work, the
microscope assembly was expanded to allow the acquisition of 4
fluorescence confocal channels simultaneously. To image cell
staining efficiency in vitro, equal numbers of MSCs stained with
each of the dyes were mixed and placed on a microscope slide with
a coverslip at a concentration of 10
6 cells/mL. For in vivo
imaging, the mouse ear was positioned under a coverslip with
methylcellulose gel and images acquired at 30 frames per second
at a depth up to 200 mm using a 60X 1.0NA water immersion
objective lens (Olympus, Center Valley, PA). DiO labeled MSCs
were excited with a 491 nm continuous wave (CW) laser (Cobalt,
Stockholm, Sweden), and detected through a 520620 nm
Figure 4. An optimized dye pair allows quantification of MSC cytokine pre-treatment impact on delivery to an inflamed site.
Systemic infusion of MSCs pretreated with TNF-a/IFN-c (blue, stained with Vybrant DiD) increases cell trafficking to the inflamed ear vs. control MSCs
(green, stained with Vybrant DiI) (a). When quantified, this yields an average increase in cells/mm
2 of ear surface area of 2262% (p,0.05, Students
unpaired t-test) (b). The increase in trafficking is of a consistent magnitude across a range of injected cell numbers with a commensurate range of
detected counts (p,0.05, 2-way ANOVA) (c). If the increase in homing for each cell dose is plotted, consistent evaluation of the homing increase is
observed, even with a wide range of injected cell numbers (d). Scale bar=100 mm.
doi:10.1371/journal.pone.0078145.g004
In Vivo Quantification of MSC Delivery
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were excited with a 561 nm CW laser (Coherent, Inc., Santa
Clara, CA) and detected through a 593 nm 640 nm filter (Omega
Optical, Brattleboro, VT). DiD labeled MSCs were excited with a
638 nm CW laser (Coherent, Inc., Santa Clara, CA) and detected
through a 695 nm 627.5 nm band pass filter (Omega Optical,
Brattleboro, VT). DiR labeled MSCs were excited using a
femtosecond Ti:Sapphire Maitai source for single photon excita-
tion at 750 nm (Spectra Physics, Santa Clara, CA) and collected
through a 785 nm 631 nm band pass filter (Omega Optical,
Brattleboro, VT).
Quantification with Dye Switch
For quantification, the average number of cells in 20
representative imaging locations across the inflamed region were
counted in each mouse. Cells were defined as having a diameter
from 10–30 mm to eliminate debris and clumps from analysis, and
a primary channel intensity greater than 2 to eliminate auto-
fluorescent events. To ensure accurate quantification of MSC
homing to the inflamed ear, the optimal dye pair was selected as
described above and used with a dye switch. In this, half of the test
animals received a solution containing DiI control cells and DiD
TNF-a/IFN-c treated cells. The other half of the test animals
receive a solution containing DiD control cells and DiI TNF-a/
IFN-c cells. The counts for DiD cells were adjusted by the relative
detection sensitivity (ratio of DiI/DiD counts) determined in the
overall dye efficiency experiments (Fig. 2b). This dye switch
allowed direct comparison of cell homing numbers and ensured
that equalization did not introduce bias into our measurements.
Statistical Analysis
For individual pairwise comparisons, an unpaired two-tailed
Student’s t-test was used. For group analyses, 1-way or 2-way
ANOVA was used, with Tukey’s HSD to evaluate multiple
pairwise comparisons. Error bars in all graphs represent standard
deviation, and statistical significance is denoted by *p,0.05.
Acknowledgments
We would like to thank our collaborators at Sanofi. Jean-Francois Deleuze,
Gerald Boquet, Christelle Perrault, and Brigitte Benhamou all provided
valuable support and discussion on this research. We would also like to
thank Kyle Tsang and Lara (Moyu) Fu for assistance with cell culture and
preparation.
Author Contributions
Conceived and designed the experiments: LJM OL JPP JMK CPL.
Performed the experiments: LJM OL JPP TS BT JPR FG. Analyzed the
data: LJM TS BT JPR FG. Contributed reagents/materials/analysis tools:
LJM OL JMK CPL. Wrote the paper: LJM OL JMK CPL.
References
1. Ortiz LA, DuTreil M, Fattman C, Pandey AC, Torres G, et al. (2007)
Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic
effect of mesenchymal stem cells during lung injury. Proceedings of the National
Academy of Sciences 104: 11002–11007.
2. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, et al. (2003) Mesenchymal
stem cells modified with Akt prevent remodeling and restore performance of
infarcted hearts. Nat Med 9: 1195–1201.
3. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, et al. (2009) Intravenous
hMSCs improve myocardial infarction in mice because cells embolized in lung
are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:
54–63.
4. Prasad VK, Lucas KG, Kleiner GI, Talano JAM, Jacobsohn D, et al. (2011)
Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells
(Prochymal
TM) in pediatric patients with severe refractory acute graft-versus-host
disease in a compassionate use study. Biol Blood Marrow Transplant 17: 534–
41.
5. von Bahr L, Sundberg B, Lo ¨nnies L, Sander B, Karbach H, et al. (2011) Long-
Term Complications, Immunologic Effects, and Role of Passage for Outcome in
Mesenchymal Stromal Cell Therapy. Biol Blood Marrow Transplant.
6. Ne ´meth K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, et al. (2009)
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent
reprogramming of host macrophages to increase their interleukin-10 production.
Nat Med 15: 42–9.
7. Hung S, Pochampally RR, Hsu S, Sanchez C, Chen S, et al. (2007) Short-term
exposure of multipotent stromal cells to low oxygen increases their expression of
CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2: e416.
8. Bartosh TJ, Ylo ¨stalo JH, Mohammadipoor A, Bazhanov N, Coble K, et al.
(2010) Aggregation of human mesenchymal stromal cells (MSCs) into 3D
spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A
107: 13724–9.
9. Segers VF, Van Riet I, Andries LJ, Lemmens K, Demolder MJ, et al. (2006)
Mesenchymal stem cell adhesion to cardiac microvascular endothelium:
activators and mechanisms. Am J Physiol Heart Circ Physiol 290: 1370–1377.
10. Shi M, Li J, Liao L, Chen B, Li B, et al. (2007) Regulation of CXCR4 expression
in human mesenchymal stem cells by cytokine treatment: role in homing
efficiency in NOD/SCID mice. Haematologica 92: 897–904.
11. Deuse T, Peter C, Fedak PWM, Doyle T, Reichenspurner H, et al. (2009)
Hepatocyte growth factor or vascular endothelial growth factor gene transfer
maximizes mesenchymal stem cell-based myocardial salvage after acute
myocardial infarction. Circulation 120: S247–54.
12. Han JY, Goh RY, Seo SY, Hwang TH, Kwon HC, et al. (2007)
Cotransplantation of cord blood hematopoietic stem cells and culture-expanded
and GM-CSF2/SCF-transfected mesenchymal stem cells in SCID mice.
J Korean Med Sci 22: 242–247.
13. Min C, Kim B, Park G, Cho B, Oh I (2007) IL-10-transduced bone marrow
mesenchymal stem cells can attenuate the severity of acute graft-versus-host
disease after experimental allogeneic stem cell transplantation. Bone Marrow
Transplant 39: 637–45.
14. Choi J, Yoo S, Park S, Kang Y, Kim W, et al. (2008) Mesenchymal stem cells
overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin
Exp Immunol 153: 269–76.
15. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, et al. (2010) Engineered
mesenchymal stem cells with self-assembled vesicles for systemic cell targeting.
Biomaterials 31: 5266–74.
16. Sarkar D, Ankrum JA, Teo GS, Carman CV, Karp JM (2011) Cellular and
extracellular programming of cell fate through engineered intracrine-, paracrine-
, and endocrine-like mechanisms. Biomaterials 32: 3053–3061.
17. Zhao W, Schafer S, Choi J, Yamanaka YJ, Lombardi ML, et al. (2011) Cell-
surface sensors for real-time probing of cellular environments. Nat Nanotechnol
6: 524–31.
18. Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, et al. (2011) Engineered
cell homing. Blood 118: e184–e191.
19. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic
in vivo distribution of bone marrow-derived mesenchymal stem cells after
infusion. Cells Tissues Organs 169: 12–20.
20. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, et al. (2003)
Systemic delivery of bone marrow-derived mesenchymal stem cells to the
infarcted myocardium: feasibility, cell migration, and body distribution.
Circulation 108: 863–868.
21. De ´gano IR, Vilalta M, Bago ´ JR, Matthies AM, Hubbell JA, et al. (2008)
Bioluminescence imaging of calvarial bone repair using bone marrow and
adipose tissue-derived mesenchymal stem cells. Biomaterials 29: 427–37.
22. Wang H, Cao F, De A, Cao Y, Contag C, et al. (2009) Trafficking mesenchymal
stem cell engraftment and differentiation in tumor-bearing mice by biolumines-
cence imaging. Stem Cells 27: 1548–1558.
23. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, et al. (2009) Direct
evidence of mesenchymal stem cell tropism for tumor and wounding
microenvironments using in vivo bioluminescent imaging. Stem Cells 27:
2614–23.
24. Ko IK, Kim B, Awadallah A, Mikulan J, Lin P, et al. (2010) Targeting improves
MSC treatment of inflammatory bowel disease. Mol Ther 18: 1365–72.
25. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, et al. (2003)
Mesenchymal stem cells home to injured tissues when co-infused with
hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.
J Gene Med 5: 1028–38.
26. Rombouts WJC, Ploemacher RE (2003) Primary murine MSC show highly
efficient homing to the bone marrow but lose homing ability following culture.
Leukemia 17: 160–70.
27. Me ´ndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et
al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone
marrow niche. Nature 466: 829–34.
28. Joo S, Cho K, Jung Y, Kim H, Park S, et al. (2011) Bioimaging for the
monitoring of the in vivo distribution of infused mesenchymal stem cells in a
mouse model of the graft-versus-host reaction. Cell Biol Int 35: 417–21.
In Vivo Quantification of MSC Delivery
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e7814529. Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, et al. (2012) Endogenous
bone marrow MSCs are dynamic, fate-restricted participants in bone
maintenance and regeneration. Cell Stem Cell 10: 259–272.
30. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, et al. (2008) Ex
vivo glycan engineering of CD44 programs human multipotent mesenchymal
stromal cell trafficking to bone. Nat Med 14: 181–7.
31. Lin YC, Leu S, Sun CK, Yen CH, Kao YH, et al. (2010) Early combined
treatment with sildenafil and adipose-derived mesenchymal stem cells preserves
heart function in rat dilated cardiomyopathy. J Transl Med 8: 88–88.
32. Sigal A, Milo R, Cohen A, Geva-Zatorsky N, Klein Y, et al. (2006) Variability
and memory of protein levels in human cells. Nature 444: 643–6.
33. Halter M, Tona A, Bhadriraju K, Plant AL, Elliott JT (2007) Automated live cell
imaging of green fluorescent protein degradation in individual fibroblasts.
Cytometry A 71: 827–34.
34. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al.
(2003) A Serious Adverse Event after Successful Gene Therapy for X-Linked
Severe Combined Immunodeficiency. New England Journal of Medicine 348:
255–256.
35. Salomatina E, Yaroslavsky AN (2008) Evaluation of the in vivo and ex vivo
optical properties in a mouse ear model. Physics in Medicine and Biology 53:
2797.
36. Mortensen LJ, Glazowski CE, Zavislan JM, Delouise LA (2011) Near-IR
fluorescence and reflectance confocal microscopy for imaging of quantum dots
in mammalian skin. Biomed Opt Express 2: 1610–1625.
37. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, et al. (2008) IFN-
gamma activation of mesenchymal stem cells for treatment and prevention of
graft versus host disease. Eur J Immunol 38: 1745–55.
38. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, et al. (2008) Human
mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce
growth factors by an NF kappa B- but not JNK-dependent mechanism.
Am J Physiol Cell Physiol 294: C675–82.
39. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, et al. (2011) Mesenchymal stem
cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-c
and TNF-a. Nat Med 17: 1594–601.
40. Prockop DJ, Youn Oh J (2012) Mesenchymal Stem/Stromal Cells (MSCs): Role
as Guardians of Inflammation. Mol Ther 20: 14–20.
41. Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in
the details. Cell Stem Cell 4: 206–16.
42. Ancin H, Roysam B, Dufresne TE, Chestnut MM, Ridder GM, et al. (1996)
Advances in automated 3-D image analyses of cell populations imaged by
confocal microscopy. Cytometry 25: 221–234.
43. Lin G, Adiga U, Olson K, Guzowski JF, Barnes CA, et al. (2003) A hybrid 3D
watershed algorithm incorporating gradient cues and object models for
automatic segmentation of nuclei in confocal image stacks. Cytometry A 56:
23–36.
44. Forero MG, Hidalgo A (2011) Image Processing Methods for Automatic Cell
Counting In Vivo or In Situ Using 3D Confocal Microscopy.
45. Veilleux I, Spencer JA, Biss DP, Cote D, Lin CP (2008) In Vivo Cell Tracking
With Video Rate Multimodality Laser Scanning Microscopy. Selected Topics in
Quantum Electronics, IEEE Journal of 14: 10–18.
In Vivo Quantification of MSC Delivery
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e78145